Concepedia

Natraj Reddy Ammakkanavar

NR

Statistics

Publications

11

Citations

551

H-Index

11

Active since

2012

Affiliations

Community Health Network(Current)

Indiana University – Purdue University Indianapolis

Memorial Sloan Kettering Cancer Center

Institut Gustave Roussy

Massachusetts General Hospital

Natraj Reddy Ammakkanavar is an author at Community Health Network specializing in medicine, oncology, and recist criteria.

Publications per year

2012–2024

11

Publications

11

Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206

Nabil Adra, Lawrence H. Einhorn, Sandra K. Althouse et al. · Annals of Oncology · 2017 · 197 citations

, , +9

Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers

Milan Radovich, Patrick J. Kiel, Stacy Marie Nance et al. · Oncotarget · 2016 · 109 citations · Full text

, , +16

Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with <i>KRAS</i> G12C-mutant advanced solid tumors.

Rebecca S. Heist, Takafumi Koyama, Yonina R. Murciano‐Goroff et al. · Journal of Clinical Oncology · 2024 · 43 citations

, , +13

Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors

Yonina R. Murciano‐Goroff, Rebecca S. Heist, Yasutoshi Kuboki et al. · Cancer Research · 2023 · 37 citations

, , +13

Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with <i>KRAS</i> G12C-mutant advanced NSCLC.

Timothy F. Burns, Konstantin H. Dragnev, Yutaka Fujiwara et al. · Journal of Clinical Oncology · 2024 · 35 citations

, , +16

1–5 of 11